Table 5 Selected ongoing and upcoming studies of BsAbs in ND MM.
From: Bispecific antibodies in the treatment of multiple myeloma
Trial | BsAb/BiTE | Phase | Patient group | No of patients | Treatment | Primary endpoint | Status | Identifier |
|---|---|---|---|---|---|---|---|---|
MajesTEC-7 | Teclistamab Talquetamab | 3 | ND MM not eligible/intended for upfront ASCT | 1590 | Teclistamab + Daratumumab + Lenalidomide vs Talquetamab + Daratumumab + Lenalidomide vs Daratumumab-Lenalidomide-Dexamethasone | MRD neg, PFS | Recruiting | NCT05552222 |
MagnetisMM-6 | Elranatamab | 2 | ND MM not eligible for ASCT | 966 | Elranatamab + Daratumumab + Lenalidomide vs Daratumumab + Lenalidomide + Dexamethasone | DLT, PFS, Sustained MRD neg | Recruiting | NCT05623020 |
MajesTEC-2 | Teclistamab | Multi-arm phase 1b study | ND MM based on treatment arm. (Arms A to F) | 140 | Arm A – Teclistamab + Daratumumab + Pomalidomide Arm B – Teclistamab + Daratumumab + Lenalidomide + Bortezomib (q21 days) Arm C – Teclistamab + Nirogacestat Arm D – Teclistamab + Lenalidomide Arm E – Teclistamab + Daratumumab + Lenalidomide Arm F – Teclistamab + Daratumumab + Lenalidomide + Bortezomib (q 28 days) | AE, DLT | Not yet recruiting | NCT04722146 |
LINKER-MM4 | Linvoseltamab | 1/2 | ND MM | 132 | Linvoseltamab | AE, DLT | Not yet recruiting | NCT05828511 |
MASTER-2 | Teclistamab | 2 | ND MM post Dara-VRD induction if MRD positive | 300 | Daratumumab + Teclistamab vs Daratumumab + Lenalidomide consolidation and maintenance, for MRD positive patients following 6 cycles of Dara-VRD induction | Sustained MRD neg | Not yet recruiting | NCT05231629 |
MajesTEC-4 | Teclistamab | 3 | ND MM post ASCT | 1572 | Teclistamab-Lenalidomide vs Lenalidomide as maintenance post ASCT | PFS | Recruiting | NCT05243797 |
MagnetisMM-7 | Elranatamab | 3 | ND MM post ASCT | 760 | Elranatamab vs Lenalidomide as maintenance post ASCT Part 1 will enroll pts who are MRD positive after ASCT Part 2 will enroll patients irrespective of MRD status post ASCT | PFS | Recruiting | NCT05317416 |
